Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients
University of Chicago Hospitals, 5841 South Maryland Avenue, Mail Code 5026, Chicago, IL 60637, USA. American Journal of Health-System Pharmacy
(Impact Factor: 1.88).
11/2006; 63(19 Suppl 5):S17-21. DOI: 10.2146/ajhp060379
The implications of the findings from clinical studies and pharmacokinetic analyses of the antiviral agent valganciclovir for dosing of the drug to prevent cytomegalovirus (CMV) disease in solid organ transplant recipients are reviewed.
Valganciclovir, an oral prodrug of ganciclovir, is as effective as oral ganciclovir for preventing CMV disease, although prophylaxis with either agent may delay CMV disease. Dosage reduction is required for both drugs in patients with renal impairment to prevent high plasma ganciclovir concentrations and toxicity. A valganciclovir dosage of 900 mg/day is required in patients with normal renal function, especially those at high risk for CMV disease, to provide adequate systemic ganciclovir exposure. Some studies suggest that a lower dosage might suffice for patients at a low risk for CMV disease.
Valganciclovir dosing should be based on renal function to avoid toxicity.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.